Bank Of America (Bofa) Lowers Biogen (NASDAQ:BIIB) Price Target to $163.00
Biogen (NASDAQ:BIIB – Get Free Report) had its price objective reduced by Bank Of America (Bofa) from $178.00 to $163.00 in a research report issued on Tuesday. The firm currently has a “neutral” rating on the biotechnology company’s stock. Bank Of America (Bofa)’s price target would suggest a potential upside of 22.16% from the stock’s […]
Biogen (NASDAQ:BIIB – Get Free Report) had its price objective reduced by Bank Of America (Bofa) from $178.00 to $163.00 in a research report issued on Tuesday. The firm currently has a “neutral” rating on the biotechnology company’s stock. Bank Of America (Bofa)’s price target would suggest a potential upside of 22.16% from the stock’s […]
